We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 01, 2020

Predictive Value of PD-L1 in Patients With Metastatic RCC Treated With Immune Checkpoint Inhibitors

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
The Predictive Value of Programmed Death Ligand 1 in Patients With Metastatic Renal Cell Carcinoma Treated With Immune-Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Eur Urol 2020 Nov 07;[EPub Ahead of Print], K Mori, M Abufaraj, H Mostafaei, F Quhal, H Fajkovic, M Remzi, PI Karakiewicz, S Egawa, M Schmidinger, SF Shariat, KM Gust

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading